CN117229246B - 具有抗炎活性的化合物及其制备方法和用途 - Google Patents
具有抗炎活性的化合物及其制备方法和用途 Download PDFInfo
- Publication number
- CN117229246B CN117229246B CN202310957818.1A CN202310957818A CN117229246B CN 117229246 B CN117229246 B CN 117229246B CN 202310957818 A CN202310957818 A CN 202310957818A CN 117229246 B CN117229246 B CN 117229246B
- Authority
- CN
- China
- Prior art keywords
- compound
- inflammatory activity
- separating
- ethyl acetate
- penicillium griseofulvum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 54
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 241000228127 Penicillium griseofulvum Species 0.000 claims abstract description 25
- 229930000044 secondary metabolite Natural products 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 8
- 238000004440 column chromatography Methods 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 22
- 239000001963 growth medium Substances 0.000 claims description 21
- 241000209094 Oryza Species 0.000 claims description 19
- 235000007164 Oryza sativa Nutrition 0.000 claims description 19
- 235000009566 rice Nutrition 0.000 claims description 19
- 239000003480 eluent Substances 0.000 claims description 18
- 238000000855 fermentation Methods 0.000 claims description 16
- 230000004151 fermentation Effects 0.000 claims description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- 239000000499 gel Substances 0.000 claims description 13
- 239000002024 ethyl acetate extract Substances 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 12
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 claims description 11
- 230000002829 reductive effect Effects 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000003208 petroleum Substances 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 238000011218 seed culture Methods 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 230000001954 sterilising effect Effects 0.000 claims description 8
- 238000010828 elution Methods 0.000 claims description 7
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 6
- 239000002609 medium Substances 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 229920001817 Agar Polymers 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 244000061456 Solanum tuberosum Species 0.000 claims description 4
- 235000002595 Solanum tuberosum Nutrition 0.000 claims description 4
- 239000008272 agar Substances 0.000 claims description 4
- 238000005520 cutting process Methods 0.000 claims description 4
- 238000002481 ethanol extraction Methods 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 238000004587 chromatography analysis Methods 0.000 claims description 3
- 238000003810 ethyl acetate extraction Methods 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 48
- 229940125904 compound 1 Drugs 0.000 description 24
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 12
- 239000011259 mixed solution Substances 0.000 description 12
- 239000013078 crystal Substances 0.000 description 10
- 206010009900 Colitis ulcerative Diseases 0.000 description 9
- 201000006704 Ulcerative Colitis Diseases 0.000 description 9
- 229940125782 compound 2 Drugs 0.000 description 8
- 229940126214 compound 3 Drugs 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 210000001072 colon Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000002158 endotoxin Substances 0.000 description 7
- 229920006008 lipopolysaccharide Polymers 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 4
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical group O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 3
- 229960000633 dextran sulfate Drugs 0.000 description 3
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 2
- 101000973778 Homo sapiens NAD(P)H dehydrogenase [quinone] 1 Proteins 0.000 description 2
- 102100022365 NAD(P)H dehydrogenase [quinone] 1 Human genes 0.000 description 2
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 2
- 241000228143 Penicillium Species 0.000 description 2
- 241000130764 Tinea Species 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229960002867 griseofulvin Drugs 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 2
- 229960004963 mesalazine Drugs 0.000 description 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
- 239000001965 potato dextrose agar Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010038063 Rectal haemorrhage Diseases 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 238000012271 agricultural production Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002983 circular dichroism Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- PSUFRPOAICRSTC-UHFFFAOYSA-N crispatine Natural products O1C(=O)C(C)C(O)(C)C(C)C(=O)OCC2=CCN3C2C1CC3 PSUFRPOAICRSTC-UHFFFAOYSA-N 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
No. | 化合物1a | 化合物2a | 化合物3b |
2 | 95.3,C | 95.7,C | 93.0,C |
3 | 190.7,C | 196.9,C | 192.7,C |
3a | 104.1,C | 107.4,C | 104.7,C |
4 | 159.1,C | 158.5,C | 158.1,C |
5 | 93.5,CH | 92.6,CH | 92.7,CH |
6 | 170.3,C | 169.7,C | 169.3,C |
7 | 88.7,CH | 88.2,CH | 88.9,CH |
7a | 176.1,C | 175.7,C | 175.1,C |
8 | 56.1,CH3 | 56.0,CH3 | 55.8,CH3 |
9 | 56.1,CH3 | 56.0,CH3 | 56.2,CH3 |
2′ | 190.6,C | 75.1,CH | 77.4,CH |
3′ | 126.7,CH | 29.2,CH2 | 31.1,CH2 |
4′ | 152.4,CH | 23.4,CH2 | 62.3,CH |
5′ | 31.3,CH2 | 28.5,CH2 | 130.5,CH |
6′ | 37.2,CH | 38.8,CH | 132.2,C |
7′ | 14.6,CH3 | 14.9,CH3 | 16.0,CH3 |
8′ | / | / | 57.2,CH3 |
Claims (9)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310584787X | 2023-05-23 | ||
CN202310584787 | 2023-05-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117229246A CN117229246A (zh) | 2023-12-15 |
CN117229246B true CN117229246B (zh) | 2024-06-07 |
Family
ID=89090038
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310957818.1A Active CN117229246B (zh) | 2023-05-23 | 2023-08-01 | 具有抗炎活性的化合物及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117229246B (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108779089A (zh) * | 2016-03-30 | 2018-11-09 | 第三共株式会社 | 灰黄霉素化合物 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2008652A1 (en) * | 2007-06-28 | 2008-12-31 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Griseofulvin analogues for the treatment of cancer by inhibition of centrosomal clustering |
-
2023
- 2023-08-01 CN CN202310957818.1A patent/CN117229246B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108779089A (zh) * | 2016-03-30 | 2018-11-09 | 第三共株式会社 | 灰黄霉素化合物 |
Non-Patent Citations (2)
Title |
---|
Dawkins, A. W. 等.Griseofulvin. XV. Some derivatives of the l,d-stereoisomer of griseofulvin.Journal of the Chemical Society.1959,1830-1834. * |
Synthesis and Structure-Activity Relationship of Griseofulvin Analogues as Inhibitors of Centrosomal Clustering in Cancer Cells;Ronnest, Mads H. 等;Journal of Medicinal Chemistry;20090429;第52卷(第10期);3342-3347 * |
Also Published As
Publication number | Publication date |
---|---|
CN117229246A (zh) | 2023-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112043713B (zh) | 白桦脂酸衍生物在制备治疗神经损伤疾病的药物中的应用 | |
CN112028964B (zh) | 一种白桦脂酸衍生物及其制备方法与应用 | |
CN106631775A (zh) | 化合物cytosporaphenone A及其制备方法和在制备抗肿瘤药物中的应用 | |
CN109232513B (zh) | 化合物lithocarpinols及其制备方法和在制备抗肿瘤药物中的应用 | |
CN111253460B (zh) | 一种具有抗炎活性的三萜类药物及其制备方法和应用 | |
CN111154658A (zh) | 一株海洋真菌、由其制备的新型骨架杂萜衍生物及其制备方法和应用 | |
CN117229246B (zh) | 具有抗炎活性的化合物及其制备方法和用途 | |
CN111533772B (zh) | 环烯醚萜类化合物的制备方法、环烯醚萜类化合物及应用 | |
CN114437011B (zh) | 一种色原酮类化合物及其制备方法与应用 | |
CN107011140B (zh) | 一种单萜类化合物及其制备方法与应用 | |
CN115521245A (zh) | 马齿苋中一种生物碱类化合物及其提取分离方法与应用 | |
CN109456196B (zh) | 一种海洋真菌来源的醌类化合物及其制备方法与应用 | |
CN115340518A (zh) | 一种青霉菌代谢产物、其提取方法和应用 | |
WO2017071577A1 (zh) | 姜黄素的生物转化方法、产物及应用 | |
CN109456292B (zh) | 一种海洋真菌来源的香豆素类化合物及其制备方法与应用 | |
CN104630078B (zh) | 四环曲霉酮类化合物及其制备方法和应用 | |
CN105837590A (zh) | 具有抗白色念珠菌活性的化合物及其制备方法和应用 | |
CN104844544B (zh) | 裂环多节孢绿胶霉素类化合物及其用途 | |
CN111233647B (zh) | 化合物Disalbaspidin PB及其在抗菌中的应用 | |
CN115300559B (zh) | 文冠果果壳皂苷在抗红色毛癣菌方面的应用及其提取纯化方法 | |
CN111808033B (zh) | 一种具有抗菌作用的新化合物的制备方法及应用 | |
CN113402385B (zh) | 源自真菌代谢产物的抗菌化合物、制备方法及应用 | |
CN108002998B (zh) | 一种萘类化合物及其制备方法和应用 | |
CN109293494B (zh) | 一种红树内生真菌来源的1,4-萘醌类化合物及其制备方法和在制备抗炎药物中的应用 | |
CN107118220B (zh) | 蛋巢菌素类化合物、制备方法及其抗神经炎症的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Country or region after: China Address after: Room 1, 2 / F, building 27, Wuhan Optics Valley International Biomedical enterprise accelerator phase 1.2, 388 Gaoxin 2nd Road, Donghu New Technology Development Zone, Wuhan City, Hubei Province, 430000 Applicant after: Hubei Tianqin Biotechnology Co.,Ltd. Address before: Room 1, 2nd Floor, Building 27, Phase 1.2, Wuhan Optics Valley International Biopharmaceutical Enterprise Accelerator, No. 388 Gaoxin Second Road, Donghu New Technology Development Zone, Wuhan City, Hubei Province, 430014 Applicant before: HUBEI TOPGENE BIOLOGICAL TECHNOLOGY CO.,LTD. Country or region before: China |
|
CB02 | Change of applicant information | ||
GR01 | Patent grant |